1. Home
  2. USNA vs RLMD Comparison

USNA vs RLMD Comparison

Compare USNA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo USANA Health Sciences Inc.

USNA

USANA Health Sciences Inc.

N/A

Current Price

$14.34

Market Cap

397.1M

Sector

Health Care

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$4.20

Market Cap

461.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
USNA
RLMD
Founded
1992
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.1M
461.9M
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
USNA
RLMD
Price
$14.34
$4.20
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.40
AVG Volume (30 Days)
177.0K
1.1M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
$1,060,902,000.00
$13,070.00
Revenue This Year
$3.90
N/A
Revenue Next Year
$6.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$12.57
$1.45
52 Week High
$31.15
$8.00

Technical Indicators

Market Signals
Indicator
USNA
RLMD
Relative Strength Index (RSI) 45.84 40.97
Support Level $12.57 $4.29
Resistance Level $15.75 $4.44
Average True Range (ATR) 0.62 0.21
MACD 0.31 0.04
Stochastic Oscillator 62.20 50.00

Price Performance

Historical Comparison
USNA
RLMD

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: